July 2023 in “Journal of Clinical Medicine” Tirzepatide might help manage PCOS in obese patients but needs more research to confirm safety and effectiveness.
[object Object] 59 citations,
August 2021 in “Frontiers in Endocrinology” GLP-1 receptor agonists, like Dulaglutide, Liraglutide, and Semaglutide, have potential benefits beyond the pancreas, including neuroprotection, pain suppression, cardiovascular protection, obesity management, and cancer treatment, but there are concerns about pancreatitis and pancreatic cancer risks.
December 2024 in “African Journal of Biomedical Research” Combining lifestyle changes and medication is most effective for managing PCOS symptoms.
August 2024 in “Nutrition Bulletin” GLP-1 receptor agonists help with weight loss but need to be combined with other treatments for best results.
4 citations,
January 2019 in “Therapeutic Advances in Endocrinology and Metabolism” Medications for PCOS don't seem to raise heart disease risk.